Morgan Stanley reports 5.76 percent stake in Eckert & Ziegler stock

Published on 10/12/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was EUR 149.3 million versus EUR 148.8 million. Eckert & Ziegler stock costs EUR 12.30 on October 12, 2026 versus the EUR 12.36 Xetra close.

Key points in brief

Morgan Stanley reported a 5.76 percent position in Eckert & Ziegler on September 18, 2026, up from 5.32 percent.
First-half 2026 revenue reached EUR 149.3 million, while adjusted EBIT was EUR 33.3 million.
Eckert & Ziegler stock was at EUR 12.30 at Lang & Schwarz on October 12, 2026, minus 0.49 percent versus the Xetra close of EUR 12.36.
The next scheduled earnings release is November 12, 2026, with full-year guidance of EUR 320.0 million revenue and EUR 80.0 million adjusted EBIT.

Isometrische 3D-Illustration der radiopharmazeutischen Lieferkette von Produktion bis Krankenhaus — Eckert & Ziegler DE0005659700 Medizintechnik: Isometrisches 3D-Diagramm der radiopharmazeutischen Wertschöpfungskette bis Klinik, Illustration mit AI erstellt.

Eckert & Ziegler stock was at EUR 12.30 at Lang & Schwarz on October 12, 2026 at 9:35 a.m. CEST, while Morgan Stanley reported a 5.76 percent position in Eckert & Ziegler after crossing the threshold on September 18, 2026. According to EQS News on September 24, 2026, the position rose from 5.32 percent to 5.76 percent.

Three dated milestones

On March 26, 2026, Eckert & Ziegler reported fiscal-year 2025 revenue of EUR 312.0 million and adjusted EBIT of EUR 77.7 million on its investor-relations page. On August 13, 2026, the company reported first-half revenue of EUR 149.3 million, versus EUR 148.8 million a year earlier, and adjusted EBIT of EUR 33.3 million, versus EUR 35.4 million. Berlin-Buch reported that net income increased to EUR 22.4 million from EUR 21.4 million.

The September 18, 2026 voting-rights change brought the latest dated corporate event. Morgan Stanley's total position included 3.09 percent voting rights and 2.67 percent through instruments, according to EQS News.

What does the stake signal mean?

The position change provides a concrete ownership marker as Eckert & Ziegler works toward its 2026 targets. Management has confirmed revenue of EUR 320.0 million and adjusted EBIT of EUR 80.0 million for fiscal year 2026, compared with EUR 312.0 million revenue and EUR 77.7 million adjusted EBIT in fiscal year 2025.

The first-half figures show the central tension: reported adjusted EBIT fell 6.00 percent year over year, while the Medical segment's adjusted EBIT rose 7.00 percent to EUR 24.9 million. The company attributed the comparison partly to license income in the prior-year period. That makes the second-half delivery against the EUR 80.0 million adjusted EBIT target the key operating test.

Next report is November 12

Stock Analysis lists November 12, 2026 as the next earnings date. The same page shows a market capitalization of EUR 773.5 million on October 9, 2026 and a 52-week range of EUR 11.91 to EUR 17.73, placing the October 12 Lang & Schwarz price below the upper end of that range.

At Lang & Schwarz, Eckert & Ziegler was trading at EUR 12.30 on October 12, 2026 at 9:35 a.m. CEST, minus 0.49 percent versus the Xetra close of October 9, 2026 at EUR 12.36. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.